Akebia Therapeutics (STU:AX9) Total Current Liabilities: €150.4 Mil (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
50 GF Score
Price €0.98
GF Value €1.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics Total Current Liabilities?

Akebia Therapeutics STU:AX9 -0.35% 50 Total Current Liabilities is €150.4 Mil as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 50/100 and a GF Value™ of €1.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Akebia Therapeutics's total current liabilities for the quarter that ended in Mar. 2026 was €150.4

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Akebia Therapeutics Total Current Liabilities Related Terms

Akebia Therapeutics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Total Current Liabilities Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.03 122.28 91.58 77.27 139.15

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.39 102.93 113.64 139.15 150.41
STU:AX9
50GF Score
Akebia Therapeutics Inc STU:AX9
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Akebia Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=41.745+3.03
+Other Current Liabilities+Current Deferred Liabilities
=92.084+2.29
=139.1

Akebia Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=31.548+12.648
+Other Current Liabilities+Current Deferred Liabilities
=102.325+3.889
=150.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €150.4 Mil mean?
Akebia Therapeutics (STU:AX9) has a Total Current Liabilities of €150.4 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Total Current Liabilities too high?
Akebia Therapeutics' current Total Current Liabilities is €150.4 Mil. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Total Current Liabilities compare to TKNO and ORGO?
Akebia Therapeutics' Total Current Liabilities of €150.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Akebia Therapeutics and its competitors. Akebia Therapeutics's current Total Current Liabilities is €150.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.15, compared to a current price of €0.98 — trading 15.2% below its estimated fair value. The current Total Current Liabilities is €150.4 Mil. Akebia Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Total Current Liabilities is €150.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.98 is trading 15.2% below its estimated GF Value™ of €1.15. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AX9:

  • Total Current Liabilities: €150.4 Mil
  • GF Value™: €1.15 vs. price of €0.98 (15.2% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score

Get the complete analysis for STU:AX9

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price
€1.15
GF Value